Cogent Biosciences, Inc.
NASDAQ:COGTBiotechnology
+$0.88 today
- Market cap
- $4.84B
- Beta
- 0.35
- P/E (TTM)
- -6.6
- EPS (TTM)
- -$5.26
Volume 2.71M
Average 2.15M
COGT Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Cogent Biosciences, Inc.NASDAQ: COGT
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents rises 42.0% from a year ago
Cash & equivalents stood at $181.17M at the end of Q2 FY2026, up 42.0% from a year earlier and down 24.9% from the prior quarter. Over 3 fiscal years it compounded at +30.7% a year.
Context
- Cash & equivalents amounted to 21.7% of total assets at the end of Q2 FY2026, down 24.7 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +42.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 312.01M USD
- Year-over-year change
- +217.8%
- 4-year CAGR
- +9.2%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 312.01M | +217.8% |
| FY2024 | 2024-12-31 | 98.17M | +84.4% |
| FY2023 | 2023-12-31 | 53.23M | -61.9% |
| FY2022 | 2022-12-31 | 139.89M | -36.3% |
| FY2021 | 2021-12-31 | 219.68M | — |
Cash & Equivalents vs competitors
How COGT compares with its peers on the latest reported figures
- COGT's Jun 2026 cash & equivalents of $181.17M is the 4th highest of the 10 companies compared; the peer median is $150M.
- Its year-over-year change of +42.0% is the 4th highest of 10, against a peer median of +21.2%.
- Cash & equivalents amounts to 21.7% of total assets for COGT, versus a peer median of 17.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $3.98B | +103.7% | +1.6% | 50.6% | |
| Aug 2026 | $720.24M | +818.2% | +56.5% | 60.3% | |
| Mar 2026 | $198.77M | -32.5% | +23.7% | 47.4% | |
| Jun 2026 | $181.17M | +42.0% | +30.7% | 21.7% | |
| Mar 2026 | $157.52M | +21.2% | +18.0% | 15.3% | |
| Jun 2026 | $150M | -39.5% | +2.5% | 16.2% | |
| Mar 2026 | $130.89M | -15.0% | +22.0% | 27.7% | |
| Sep 2026 | $86.84M | +48.8% | +23.3% | 8.4% | |
| Mar 2026 | $62.1M | +24.5% | -34.7% | 17.8% | |
| Mar 2026 | $39.08M | -23.8% | +42.2% | 6.0% | |
| Peer median (excluding COGT) | $150M | +21.2% | +22.0% | 17.8% | |
Competitors are the stored peer set for COGT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 219.68M | 139.89M | 53.23M | 98.17M | 312.01M |
| Short-term Investments | 0 | 119.39M | 212.48M | 188.91M | 588.75M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 1.26M | 5.06M | 9.4M | 9.59M |
| Total Current Assets | 222.63M | 264.97M | 270.77M | 296.47M | 910.36M |
| Property, Plant & Equipment (Net) | 4.48M | 31.1M | 30.34M | 26.56M | 23.54M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 1.26M | 0 | 7.46M | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.73M | 4.75M | 4.86M | 4.86M | 3.72M |
| Total Non-current Assets | 9.46M | 35.84M | 42.67M | 31.43M | 27.25M |
| Total Assets | 232.09M | 300.81M | 313.44M | 327.9M | 937.61M |
| Account Payables | 3.48M | 5.84M | 10.66M | 12.01M | 9.5M |
| Short-term Debt | 0 | 0 | 0 | 0 | 1.55M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 3.06M | 1.7M | 0 | 0 | 0 |
| Other Current Liabilities | 3.62M | 6.47M | 10.32M | 12.63M | 52.9M |
| Total Current Liabilities | 17.08M | 26.85M | 38.17M | 55.71M | 63.95M |
| Long-term Debt | 0 | 0 | 0 | 0 | 237.25M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | (14.32M) |
| Total Non-current Liabilities | 831K | 18.23M | 17.47M | 15.9M | 237.28M |
| Total Liabilities | 17.91M | 45.08M | 55.64M | 71.61M | 301.24M |
| Common Stock | 44K | 70K | 86K | 110K | 161K |
| Retained Earnings | (270.97M) | (411.21M) | (603.62M) | (859.48M) | (1.19B) |
| Accumulated OCI | (0) | (104K) | 246K | 447K | 355K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 214.18M | 255.74M | 257.8M | 256.29M | 636.37M |
| Total Debt | 3.16M | 19.65M | 18.85M | 17.47M | 253.15M |
| Net Debt | (216.53M) | (120.24M) | (34.38M) | (80.7M) | (58.86M) |
Cogent Biosciences, Inc.
NASDAQ:COGT
Intrinsic Alpha fair value
Locked
Current Price
$27.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.